Discover the latest news, events and opportunities to collaborate between business and academia here at Imperial

Not displaying correctly?

View in browser

Imperial-enterprise_Logo-black-clear

Enterprise newsletter

DECEMBER 2025 / THE SCIENCE SHAPING SOCIETY

What we achieved together in 2025

 

As we approach the end of the year, we’d like to say a massive thank you to you, our friends and collaborators, for joining our mission to use science to improve the world. 

 

Together, we moved advanced research closer to market. Pfizer’s eventual $10 billion acquisition of Metsera to advance Imperial obesity drug candidates was a landmark deal –providing Pfizer with potentially transformative new treatments. 

  

Meanwhile, Biocentis secured $19 million to trial gene-edited insects for disease control, and M-Spin advanced materials needed for the energy transition through its new pilot lab. These and many other ventures have been supported by investors who will share in the commercial upside of the innovations.  

  

This year, we also co-founded the London Quantum Technology Cluster with leading universities to give collaborators access to research and technology in a field that could transform numerous sectors. We led EarthScale’s inaugural climate-tech cohort, in which a network of universities is helping shape sustainability ventures. 

  

Strategic alliances with global reach 

In a busy year for new and growing partnerships, Mars and Intesa Sanpaolo joined Imperial Business Partners, gaining direct engagement with researchers and startups to explore innovation in sustainability and fintech. The launch of the Frontier AI Lab with Thomson Reuters is helping position our collaborators and us at the leading edge of trusted AI.  

  

Championing inclusive entrepreneurship  

We celebrated innovation through WE Innovate, where industry mentors guided women-led ventures tackling climate-proof farming and lingerie design. The launch of the UK’s first university network for women entrepreneurs created new opportunities for engagement with founders. Recognition as Outstanding Entrepreneurial University of the Year reflects the strength of this shared ecosystem.  

  

Connecting innovation across borders  

From expanding support for deep tech at WestTech London and in San Francisco, to supporting startups at the Commonwealth Fellowship bootcamp in Ghana, our collaborators played a vital role – gaining visibility, networking opportunities, and access to ventures shaping global markets. We also celebrated entrepreneurial success through the Venture Catalyst Challenge, where Reporti’s live-event safety platform took the top prize.  

  

Thank you for being part of this journey.  
Let’s build on this momentum and create even greater impact together in 2026.

Get involved

Key note speaker at the Imperial Investor Network

Imperial Investor Showcase: May 2026


This event for angel, early-stage and venture capital investors will showcase businesses from across Imperial's ecosystem, including rapid-fire pitches and networking.


6 May 2026, 18:00 - 21:00

London venue TBC

Sign up

Next in technology

Weight loss blockbusters

Blockbuster weight-loss drugs like WeGovy are transforming obesity treatment, built on the discovery by Imperial’s Professor Steve Bloom that the gut hormone GLP-1 helps control appetite. Now a candidate first developed by Professor Bloom and colleagues could lead the next generation of GLP-1 treatments.

The discovery that launched a new wave of weight loss drugs

Dyes made sustainably from algae

Microalgae is being used to make biodegradable dyes for textiles, cosmetics and food, using a low-energy and low-cost alternative to synthetic dyes. The dyes are being offered by Imperial spinout Brilliant Dyes, which has been recognised with an H&M Foundation Global Change Award.

Sustainable dyes being developed at Imperial win H&M Global Change Award

Drug candidate shows promise for breast cancer

An Imperial drug candidate could help treat breast cancers that have become resistant to hormone-based treatments. The compound, samuraciclib, is the most advanced candidate in a potential new class of drugs that inhibit the CDK7 enzyme, and has recently delivered strong Phase 2 trial results. 

Imperial drug candidate for breast cancer delivers positive Phase 2 results

Plant-based insulation offers alternative to goose down

BioPuff is a first-of-its-kind insulation material that offers the thermal properties of goose down at lower cost. Startup Ponda has partnered with brands such as Berghaus and Stella McCartney to demonstrate Biopuff’s performance in real-world conditions, and raised $2.4 million seed funding to further develop it.

Ponda wraps up $2.4 million to commercialise regenerative insulation BioPuff
Toy Truck being hit with laser beams

Collaborate. 

Explore.

Innovate.

Stay in touch


To explore how Imperial Enterprise
could help your business benefit from
Imperial’s world-leading expertise,
technologies, resources and talented
innovators, view our LinkedIn, website
or drop us a line today.

LinkedIn
Our website
Contact us

Been forwarded this newsletter? Subscribe here

    You have received this email because you subscribed to the Enterprise Newsletter or agreed to receive communications from Imperial Enterprise.

     

    This email was sent from enterprise@imperial.ac.uk

     

    Copyright © Imperial College London, All rights reserved.

    Imperial Enterprise, MediaWorks, 191 Wood Lane, London, W12 7FP, United Kingdom

    Unsubscribe Manage Preferences